|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.310 USD | -2.96% |
|
-1.50% | -28.02% |
| 07-23 | Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026 | CI |
| 07-22 | Alzamend Neuro, Inc. Auditor Raises 'Going Concern' Doubt | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 6.28M | - | - | - | - | - |
| 48.53B | |||||
| 39.87B | - | - | - | - | - |
| 38.68B | |||||
| 35.13B | |||||
| 29.79B |
- Stock Market
- Stocks
- ALZN Stock
- Charts Alzamend Neuro, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
